SOCS3 and cardiomyopathy: Overall, our findings highlight dexamethasone, resveratrol and curcumin as promising SOCS3-targeting agents for treating sepsis-induced lung injury and cardiomyopathy, paving the way for further in vitro, in vivo and clinical development.